Overview

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-12-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborator:
Shanghai Ming Ju Biotechnology Co., Ltd.
Treatments:
Cyclophosphamide
Fludarabine